Back to results
US 5,932,595 AGranted
Matrix metalloprotease inhibitors
AssigneesSyntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.
InventorsSteven Lee Bender, Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Lawrence Emerson Fisher, Robert Than Hendricks, Keshab Sarma
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.
Claims60
A compound of the formula:
- ##STR39## wherein:
- n is 0, 1 or 2;
- Y is hydroxy or XONH--, where X is hydrogen or lower alkyl;
- R.sup.1 is hydrogen or lower alkyl;
- R.sup.2 is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocylo-lower alkyl, heterocyclo-lower heteroalkyl or --NR.sup.6 R.sup.7, wherein:
- R.sup.6 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl;
- R.sup.7 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, --C(O)R.sup.8, --C(O)NR.sup.8 R.sup.9, --SO.sub.2 NR.sup.8 R.sup.9, --SO.sub.2 R.sup.10, aryloxycarbonyl, or alkoxycarbonyl;
- or
- R.sup.6 and R.sup.7 together with the nitrogen atom to which they are attached represent a heterocyclo group;
- wherein
- R.sup.8 and R.sup.9 are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl;
- and
- R.sup.10 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo;
- or
- R.sup.1 and R.sup.2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group;
- R.sup.3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy;
- R.sup.4 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl;
- or
- R.sup.2 and R.sup.3 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group;
- or
- R.sup.3 and R.sup.4 together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group;
- and
- R.sup.5 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;
- or a pharmaceutically acceptable salt or ester thereof provided that:
- (a) when n.dbd.O, then Y.dbd.XONH;
- and
- (b) when Y.dbd.OH and n=1 or 2, then
- (i) R.sub.1 and R.sub.2 or R.sub.3 and R.sub.4, together with the carbons to which they are attached form a heterocyclo group;
- or
- (ii) R.sub.1 is lower alkyl, and
- R.sub.2 is heteroalkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocyclo, heterocyclo-lower alkyl or heterocyclo-lower heteroalkyl.
28 more elements
A process for preparing a compound of the Formula:
- ##STR40## wherein:
- n is 1 or 2;
- Y is hydroxy or XONH--, where X is hydrogen or lower alkyl;
- R.sup.1 is hydrogen or lower alkyl;
- R.sup.2 is hydrogen, lower alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, or heterocyclo;
- or
- R.sup.1 and R.sup.2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group;
- R.sup.3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroaralkyl, or lower alkoxy;
- R.sup.4 is hydrogen or lower alkyl;
- or
- R.sup.2 and R.sup.3 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group;
- or
- R.sup.3 and R.sup.4 together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group;
- and
- R.sup.5 is lower alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;
- comprising contacting a compound of the Formula:
- ##STR41## with an oxidizing agent.
14 more elements
Dependencies are inferred from the claim text.